Voyageur Pharmaceuticals Ltd. VYYRF
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -15.00% | 2,700.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.00% | 2,700.00% | |||
| Cost of Revenue | -15.00% | 975.00% | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 47.64% | -24.46% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.61% | -21.74% | |||
| Operating Income | -47.62% | 24.18% | |||
| Income Before Tax | -58.94% | 26.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.94% | 26.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.94% | 26.39% | |||
| EBIT | -47.62% | 24.18% | |||
| EBITDA | -47.64% | 24.19% | |||
| EPS Basic | -57.69% | 25.71% | |||
| Normalized Basic EPS | -56.25% | 27.27% | |||
| EPS Diluted | -57.69% | 25.71% | |||
| Normalized Diluted EPS | -56.25% | 27.27% | |||
| Average Basic Shares Outstanding | 0.24% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.24% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||